Core Insights - The flu season in the U.S. is intensifying, with a new strain raising concerns about the effectiveness of current vaccines against it [3][4][15] - Public health experts indicate that while the flu season is in a high transmission phase, it has not yet peaked, and the increase in cases aligns with historical patterns [3][4][15] - COVID-19 cases remain low, with wastewater monitoring showing virus levels significantly below summer peak levels [3][4][18] Flu Season Dynamics - The current flu season is driven by a new strain of the H3N2 virus, which has become the dominant strain in the U.S. [9][20] - The CDC reports a significant rise in flu-related hospitalizations, emergency visits, and deaths, with projections indicating the peak may occur in February [4][20] - As of now, there are at least 4.6 million flu cases, over 49,000 hospitalizations, and approximately 1,900 deaths reported [20][21] Vaccine Effectiveness Concerns - Experts express concern that the new strain may reduce the effectiveness of the flu vaccine, potentially leading to increased hospitalizations [10][11][20] - Approximately 40% of U.S. adults have received the current flu vaccine, with slightly lower rates among children [21] - Despite the emergence of the new strain, vaccination remains crucial to reduce severe illness and hospitalization risks [21][22] Public Health Recommendations - Public health officials continue to urge the public to complete COVID-19 vaccinations and conduct testing as winter approaches [18] - The flu season is expected to last until March or April, with the potential for severe impacts if vaccination rates do not improve [20][22] - There is a noted increase in flu symptoms among children, highlighting the importance of timely diagnosis and treatment [21][22]

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors and guests o ...

Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [4] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [4] Upcoming Event - James Martin, CFO and co-CEO of Cocrystal, will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, at 10:00 am Eastern time [1] - The conference will take place at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida [1] - Interested investors can attend the conference at a discounted rate using the code COCPNOBLECON [2] - A video webcast of the presentation will be available on December 4, 2025, and archived for 90 days on the company's website [2] About Noble Capital Markets - Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984 [3] - The firm provides institutional-quality equity research, merchant and investment banking, and order execution services [3] - In 2018, Noble launched Channelchek, an investor community dedicated to public small and micro-cap companies, offering free institutional-quality research without a subscription [3]